Rosiglitazone and New Insights in the BARI 2D Trial

Summary

According to post hoc analyses of the Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes [BARI 2D; NCT00006305] data, rosiglitazone is not associated with an increased risk of major adverse cardiovascular events, including myocardial infarction and death, in patients with type 2 diabetes mellitus and established coronary artery disease.

  • Interventional Techniques & Devices
  • Diabetes Mellitus
  • Coronary Artery Disease
  • Diabetes & Endocrinology Clinical Trials
View Full Text